Kezar Life Sciences, Inc. (KZR) Financial Ratios
10 years of historical data (2016–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.76
↓-99% vs avg
5yr avg: 133.06
30Y Low0.7·High175.7
ROE
↓
-59.9%
↑-36% vs avg
5yr avg: -44.2%
30Y Low-60%·High-29%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
KZR Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Kezar Life Sciences, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $54M | $46M | $490M | $6.9B | $47.4B | $88.2B | $23.0B | $7.7B | $44.9B | — | — |
| Enterprise Value | $-15695667 | $-23528762 | $464M | $6.9B | $47.4B | $88.2B | $23.0B | $7.6B | $44.9B | — | — |
| P/E Ratio → | -0.95 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | 981.55 | — | — | — | — | — | — | — |
| P/B Ratio | 0.76 | 0.66 | 4.19 | 36.63 | 175.74 | 448.07 | 162.93 | 98.05 | 412.66 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
KZR EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | 979.18 | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
KZR Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -59.9% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | 100.0% | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | -1591.8% | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | -1455.3% | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -59.9% | -59.9% | -55.0% | -44.5% | -29.2% | -32.3% | -38.1% | -37.6% | -55.8% | — | — |
| ROA | -50.6% | -50.6% | -45.8% | -39.1% | -26.4% | -29.5% | -34.6% | -34.4% | -27.4% | -25.9% | -78.7% |
| ROIC | -85.3% | -85.3% | -51.8% | -39.6% | -26.8% | -30.0% | -33.1% | -37.0% | -469.8% | — | — |
| ROCE | -53.8% | -53.8% | -55.3% | -45.3% | -28.6% | -30.8% | -37.6% | -39.0% | -30.1% | -27.6% | -83.4% |
KZR Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $72M exceeds total debt of $2M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.14 | 0.10 | 0.08 | 0.07 | 0.04 | 0.08 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.99 | -0.22 | -0.09 | -0.07 | -0.25 | -0.11 | -0.11 | -0.22 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -51.56 | -64.72 | -56.59 | -342.58 | — | — | — | — | — |
Net cash position: cash ($72M) exceeds total debt ($2M)
KZR Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Kezar Life Sciences, Inc.'s current ratio of 11.52x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 11.66x to 11.52x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.52 | 11.52 | 6.76 | 11.66 | 25.98 | 25.77 | 22.48 | 13.52 | 32.91 | 35.26 | 16.11 |
| Quick Ratio | 11.52 | 11.52 | 6.76 | 11.66 | 25.98 | 25.77 | 22.48 | 13.52 | 32.91 | 35.26 | 16.11 |
| Cash Ratio | 10.93 | 10.93 | 6.51 | 11.35 | 25.15 | 25.37 | 21.80 | 13.03 | 32.19 | 34.39 | 14.97 |
| Asset Turnover | — | — | — | 0.03 | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | 119.46 | — | — | — | — | — | — | — |
KZR Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Kezar Life Sciences, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $7M | $73M | $73M | $67M | $53M | $44M | $19M | $19M | $13M | $13M |
Peer Comparison
Compare KZR with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 KZRYou | $54M | -1.0 | — | — | — | — | -59.9% | -85.3% | — |
 IMVT | $7B | -12.1 | — | — | — | — | -64.8% | — | — |
 ARQT | $3B | -187.5 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 PRAX | $8B | -19.8 | — | — | — | — | -45.8% | -65.0% | — |
 TGTX | $8B | 17.9 | 62.8 | — | 83.7% | 20.0% | 102.8% | 16.4% | 2.1 |
 CABA | $491M | -1.8 | — | — | — | — | -127.0% | -429.6% | — |
 RCUS | $2B | -7.2 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 HRMY | $2B | 12.7 | 6.3 | 5.7 | 77.2% | 24.0% | 20.8% | 42.0% | 1.0 |
 VKTX | $3B | -9.0 | — | — | — | — | -47.3% | -44.4% | — |
 ACAD | $4B | 9.2 | 25.1 | 34.3 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 INVA | $2B | 6.9 | 6.8 | 8.6 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
| Healthcare Median | — | 22.9 | 14.4 | 18.9 | 63.9% | -4.3% | -32.6% | -11.4% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 10 years · Updated daily
What if you invested $1,000 in KZR 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in KZR be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs KZR Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationKZR vs IMVT — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Immunovant, Inc..
Compare NowKZR — Frequently Asked Questions
Quick answers to the most common questions about buying KZR stock.
What is Kezar Life Sciences, Inc.'s P/E ratio?
Kezar Life Sciences, Inc.'s current P/E ratio is -1.0x. This places it at the 50th percentile of its historical range.
What is Kezar Life Sciences, Inc.'s ROE?
Kezar Life Sciences, Inc.'s return on equity (ROE) is -59.9%. The historical average is -44.1%.
Is KZR stock overvalued?
Based on historical data, Kezar Life Sciences, Inc. is trading at a P/E of -1.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.